Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Betula nigra pollen extract is a non-standardized biologic allergenic extract derived from the pollen of the river birch tree (Betula nigra). [5] It is indicated for both the diagnosis (via skin testing) and treatment (via immunotherapy) of individuals with immediate hypersensitivity allergies to river birch pollen. [3] The product works through allergen-specific immunotherapy, a process that desensitizes the patient's immune system to the specific pollen allergens by administering gradually increasing doses of the extract, which can reduce or eliminate allergic symptoms. [1, 3] This treatment is typically administered via percutaneous, subcutaneous, or intradermal injection. It is marketed by several companies, including Allergy Laboratories, Inc. under the brand name River Birch Pollen.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Betula nigra pollen extract.